COVID-19 vaccine at Novavax labs in Gaithersburg, Maryland, United States on March 20, 2020. (AFP/VNA Photo)In anannouncement, Novavax chief executive Stanley Erck affirmed the company’s commitmentto equitable global access and will fill a need for Indonesia, the fourth mostpopulous nation on earth.
The vaccinewill be produced by the Serum Institute of India (SII), and deliveries willbegin "imminently," according to a statement from Novavax.
Nonavax andits partner Serum Institute of India (SII) in September applied to the WorldHealth Organisation for an emergency use listing of Novavax's COVID-19 vaccine,clearing the way for the shot to be shipped to countries participating in the COVID-19Vaccines Global Access Facility (COVAX).
The twocountries have committed to providing more than 1.1 billion doses of vaccine toCOVAX to facilitate equal access to vaccines for low and middle-incomecountries. Clinical trials in the United States and Mexico showed that Novavax'svaccine has an efficacy of 90.4 percent./.